Risk and Radical Uncertainty in HIV Research

Abstract

Evaluating allowable risk for research subjects who interrupt established therapies, such as antiretroviral treatment for HIV, is complicated when available evidence supports only imprecise probability intervals rather than exact risks. In assessing whether such risks exceed acceptable thresholds, decision-makers may adopt an optimistic, moderate, or pessimistic approach, evaluating risk according to the interval’s lower bound, mid-point, or upper bound, respectively. Although decision theory frequently favors optimistic models to broaden permissible choices, distinct practical and ethical considerations support the pessimistic approach in clinical research. Because research studies systematically generate statistical evidence, initial imprecise confidence intervals contract and shift as data accumulate. Adopting optimistic or moderate standards introduces a high probability that emerging evidence will revise risk assessments upward, rendering continued participation impermissible by the researchers’ own standards. This forces investigators either to willfully disregard incoming data or to withdraw subjects prematurely, resulting in wasted scientific resources. Evaluating prospective trials using the most pessimistic precisification minimizes the risk of study disruptions and ensures that participant exposure remains ethically justifiable throughout the trial. – AI-generated abstract.